Helicobacter pylori:: the challenge in therapy
Helicobacter pylori:: the challenge in therapy
复制标题
DOI：
10.1046/j.1523-5378.7.s1.7.x
复制
发表时间：
2002-01-01
期刊：
影响因子：
4.4
通讯作者：
Rokkast, T
中科院分区：
文献类型：
--
作者：
Bazzoli, F;Pozzato, P;Rokkast, T
对于幽门螺杆菌感染的治疗管理，马斯特里赫特2-2000共识报告引入了“治疗包”的概念，将一线和二线根除治疗放在一起考虑。根据这一共识声明，H。幽门根除是质子泵抑制剂（PPI）或枸橼酸铋雷尼替丁（RBC）和克拉霉素加阿莫西林或甲硝唑的组合。二线治疗建议为PPI四联疗法，至少7天。如果铋化合物不可用，则仅在药敏试验后才可将基于PPI的三联疗法用作二线治疗。由于在过去的一年中在治疗方案方面没有取得相当大的进展，仍然需要对H. pylori，这可能成为未来的治疗方法。
For the therapeutic management of Helicobacter pylori infection, the Maastricht 2-2000 Consensus Report have introduced the concept of the 'treatment package' that considers first- and second-line eradication therapies together. According to this consensus statement, the first-line therapy for H. pylori eradication is a combination of the proton pump inhibitors (PPI) or ranitidine bismuth citrate (RBC) and claritromycin plus either amoxicillin or metronidazole. The second- line treatment is suggested to be PPI-quadruple therapy for a minimum of 7 days. If bismuth compounds arc not available, PPI-based triple therapy will have to be used as a second-line treatment only after susceptibility testing. Since no considerable progress has been made during the past year in treatment regimens, there is still a need for new compounds that are specific for H. pylori, which could constitute future therapies.